Brent A Orr

List of Publications by Year
in descending order

89 papers	4,865 citations	117625 34 h-index	106344 65 g-index
94 all docs	94 docs citations	94 times ranked	7349 citing authors

#	Article	IF	Citations
1	Pre-operative embolization for staged treatment of infantile choroid plexus papilloma. Child's Nervous System, 2022, 38, 429-433.	1.1	4
2	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-Oncology, 2022, 24, 1166-1175.	1.2	2
3	The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Developmental Cell, 2022, 57, 1226-1240.e8.	7.0	24
4	MEDB-42. GermlineElp1 deficiency promotes genomic instability and survival of granule neuron progenitors primed for SHH medulloblastoma pathogenesis. Neuro-Oncology, 2022, 24, i115-i115.	1.2	0
5	MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 2022, 24, i124-i125.	1.2	1
6	ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis. Neuro-Oncology, 2022, 24, i8-i8.	1.2	1
7	Primary cilia control translation and the cell cycle in medulloblastoma. Genes and Development, 2022, 36, 737-751.	5.9	14
8	Biology and grading of pleomorphic xanthoastrocytomaâ€"what have we learned about it?. Brain Pathology, 2021, 31, 20-32.	4.1	32
9	Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. Neuro-Oncology Advances, 2021, 3, vdaa168.	0.7	6
10	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	7.7	44
11	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
12	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	1.6	106
13	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical Cancer Research, 2021, 27, 2879-2889.	7.0	35
14	Molecular classification of a complex structural rearrangement of the RB1 locus in an infant with sporadic, isolated, intracranial, sellar region retinoblastoma. Acta Neuropathologica Communications, 2021, 9, 61.	5.2	5
15	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	9.4	88
16	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nature Communications, 2021, 12, 4089.	12.8	27
17	Retinoblastoma from human stem cell-derived retinal organoids. Nature Communications, 2021, 12, 4535.	12.8	48
18	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0

#	Article	IF	Citations
19	Lorlatinib in a Child with ALK-Fusionâ€“Positive High-Grade Glioma. New England Journal of Medicine, 2021, 385, 761-763.	27.0	27
20	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. Nature Communications, 2021, 12, 5531.	12.8	31
21	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099.	9.4	109
22	YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. American Journal of Surgical Pathology, 2021, 45, 329-340.	3.7	14
23	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	16.8	64
24	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19.	1.2	0
25	Methylation profiling reveals novel molecular classes of rhabdomyosarcoma. Scientific Reports, 2021, 11, 22213.	3.3	8
26	EPCO-26. INTEGRATIVE MULTI-OMICS IDENTIFIES CONVERGING DEVELOPMENTAL ORIGINS OF DISTINCT MEDULLOBLASTOMA SUBGROUPS. Neuro-Oncology, 2021, 23, vi7-vi7.	1.2	0
27	Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neuro-Oncology Advances, 2021, 3, vdab179.	0.7	5
28	An update on the central nervous system manifestations of Liâ€“Fraumeni syndrome. Acta Neuropathologica, 2020, 139, 669-687.	7.7	44
29	Treatment of pediatric highâ€grade central nervous system tumors with highâ€dose methotrexate in combination with multiagent chemotherapy: A singleâ€institution experience. Pediatric Blood and Cancer, 2020, 67, e28119.	1.5	5
30	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica, 2020, 139, 259-271.	7.7	36
31	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	7.7	50
32	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. Acta Neuropathologica, 2020, 140, 595-597.	7.7	7
33	Functional loss of a noncanonical BCORâ€“PRC1.1 complex accelerates SHH-driven medulloblastoma formation. Genes and Development, 2020, 34, 1161-1176.	5.9	16
34	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathologica, 2020, 140, 209-225.	7.7	45
35	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	27.8	94
36	Multiplatform Molecular Profiling Reveals Epigenomic Intratumor Heterogeneity in Ependymoma. Cell Reports, 2020, 30, 1300-1309.e5.	6.4	11

#	Article	IF	Citations
37	An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling. Cancer Research, 2020, 80, 1524-1537.	0.9	10
38	De novo primary central nervous system pure erythroid leukemia/sarcoma with t(1;16)(p31;q24) NFIA/CBFA2T3 translocation. Haematologica, 2020, 105, e194-e197.	3.5	9
39	Pathology, diagnostics, and classification of medulloblastoma. Brain Pathology, 2020, 30, 664-678.	4.1	68
40	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathologica, 2020, 139, 1071-1088.	7.7	50
41	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
42	Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case. Journal of Pediatric Hematology/Oncology, 2020, 42, e813-e818.	0.6	6
43	Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.. Journal of Clinical Oncology, 2020, 38, 10542-10542.	1.6	4
44	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	27.8	273
45	Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. Clinical Cancer Research, 2019, 25, 5925-5936.	7.0	22
46	H3 K27M Mutations in Thalamic Pilocytic Astrocytomas with Anaplasia. World Neurosurgery, 2019, 124, 87-92.	1.3	6
47	Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2019, 103, 728-737.	0.8	10
48	Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. Acta Neuropathologica Communications, 2019, 7, 42.	5.2	57
49	Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro-Oncology, 2019, 21, 1319-1330.	1.2	63
50	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
51	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. JCO Precision Oncology, 2019, 3, 1-21.	3.0	6
52	Alternative lengthening of telomeres, ATRX loss and H3â€K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathology, 2019, 29, 126-140.	4.1	54
53	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. Journal of the Endocrine Society, 2019, 3, .	0.2	0
54	ATPâ€dependent efflux transporter ABCC4 is a positive regulator of the Sonic Hedgehog signaling pathway. FASEB Journal, 2019, 33, 675.19.	0.5	0

#	Article	IF	Citations
55	Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases. Child's Nervous System, 2018, 34, 605-610.	1.1	12
56	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. Acta Neuropathologica, 2018, 136, 315-326.	7.7	26
57	Bithalamic gliomas may be molecularly distinct from their unilateral highâ€grade counterparts. Brain Pathology, 2018, 28, 112-120.	4.1	26
58	Central Nervous System-type Neuroepithelial Tumors and Tumor-like Proliferations Developing in the Gynecologic Tract and Pelvis. American Journal of Surgical Pathology, 2018, 42, 1429-1444.	3.7	18
59	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer, 2018, 124, 4168-4180.	4.1	64
60	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784.	10.7	151
61	Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Scientific Reports, 2018, 8, 8733.	3.3	17
62	Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma. Pediatric Blood and Cancer, 2017, 64, e26416.	1.5	11
63	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Reports, 2017, 18, 2907-2917.	6.4	61
64	Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?. International Journal of Radiation Oncology Biology Physics, 2017, 99, 450-458.	0.8	8
65	Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination. Acta Neuropathologica, 2017, 134, 159-162.	7.7	33
66	The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro-Oncology, 2017, 19, 1361-1371.	1.2	17
67	Pineoblastomaâ€"The Experience at St. Jude Children's Research Hospital. Neurosurgery, 2017, 81, 120-128.	1.1	43
68	mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. Developmental Cell, 2017, 43, 673-688.e5.	7.0	48
69	Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors. Journal of Neurosurgery: Pediatrics, 2017, 20, 247-255.	1.3	16
70	Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget, 2017, 8, 69295-69302.	1.8	99
71	NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors. Acta Neuropathologica Communications, 2016, 4, 55.	5.2	9
72	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature, 2016, 530, 57-62.	27.8	318

#	Article	IF	Citations
73	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
74	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. Acta Neuropathologica, 2016, 131, 299-307.	7.7	38
75	Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas. Journal of Neurosurgery: Pediatrics, 2016, 17, 57-65.	1.3	20
76	PM-05 * TUMOR LOCATION REMODELS TRANSCRIPTOMIC PROFILES IN A PEDIATRIC MEDULLOBLASTOMA XENOGRAFT. Neuro-Oncology, 2015, 17, iii32-iii32.	1.2	0
77	Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro-Oncology, 2015, 17, 1620-1627.	1.2	24
78	Molecular Pathways: Not a Simple Tubeâ€"The Many Functions of Blood Vessels. Clinical Cancer Research, 2015, 21, 18-23.	7.0	10
79	Enophthalmos and Choroidal Atrophy after Intraophthalmic Artery Chemotherapy for Retinoblastoma. Ophthalmology, 2015, 122, 435-437.	5.2	14
80	Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro-Oncology, 2015, 17, 882-888.	1.2	64
81	Oncogenic KRAS promotes malignant brain tumors in zebrafish. Molecular Cancer, 2015, 14, 18.	19.2	48
82	Atypical teratoid/rhabdoid tumor (ATRT) arising from the 3rd cranial nerve in infants: a clinical-radiological entity?. Journal of Neuro-Oncology, 2015, 124, 175-183.	2.9	12
83	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€"Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 2015, 33, 2646-2654.	1.6	368
84	A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathologica, 2015, 130, 575-585.	7.7	50
85	Cervicomedullary tumors in children. Journal of Neurosurgery: Pediatrics, 2015, 16, 357-366.	1.3	29
86	Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. Neuro-Oncology, 2015, 17, 448-456.	1.2	44
87	Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget, 2015, 6, 3165-3177.	1.8	66
88	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	3.8	250
89	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro-Oncology, 0, , .	1.2	7